

## **Radiation Therapy Prostate Cancer Request**

For NON-URGENT requests, please complete this document for authorization along with any relevant clinical documentation requested within this document (i.e. radiation therapy consultation, comparison plan, etc.) before submitting the case by web, phone, or fax. Failure to provide all relevant information may delay the determination. Phone and fax numbers can be found on eviCore.com under the Guidelines and Fax Forms section. You may also log into the provider portal located on the site to submit an authorization request. URGENT (same day) requests must be submitted by phone.

| Patient/<br>Member   | First Name:  |  | Middle Initial:          |       | Last Name:          |       |  |      |  |  |  |  |  |
|----------------------|--|--|--------------------------|-------|---------------------|-------|--|------|--|--|--|--|--|
|                      | DOB (mm/dd/yyyy):  |  |                          |       | Gender: Male Female |       |  |      |  |  |  |  |  |
|                      | Health Plan:   |  |                          |       | mber ID:            |       |  |      |  |  |  |  |  |
|                      |  |  |                          |       |                     |       |  |      |  |  |  |  |  |
| Clinical Information | ICD-   | CD-10 Code(s):   |                          |       |                     |       |  |      |  |  |  |  |  |
|                      | Wha  | What is the radiation therapy treatment start date (mm/dd/yyyy)?   |                          |       |                     |       |  |      |  |  |  |  |  |
|                      | For best results, the answers to these questions should be submitted online. |  |                          |       |                     |       |  |      |  |  |  |  |  |
|                      | 1.   | Does the patient have a history of distant metastases (stage M1) (i.e. to brain, lung, liver, bone)?   |                          |       |                     |       |  | ☐ No |  |  |  |  |  |
|                      | 2.   | What is the treatment intent?  |                          |       |                     |       |  |      |  |  |  |  |  |
|                      |  | <ul> <li>□ Definitive/curative (no prior surgery)</li> <li>□ Oligometastases/curative</li> <li>□ Post prostatectomy</li> <li>□ Palliative (non-curative, to alleviate symptoms)</li> <li>□ Other:</li> </ul> |                          |       |                     |       |  |      |  |  |  |  |  |
|                      | 3.   | What was the T stage at initial  | diagnosis?               |       |                     |       |  |      |  |  |  |  |  |
|                      |  | ☐ T0 ☐ T2a<br>☐ T1a ☐ T2b<br>☐ T1b ☐ T2c<br>☐ T1c ☐ T3a  | ☐ T3b<br>☐ T4<br>☐ Other |       |                     |       |  |      |  |  |  |  |  |
|                      | 4.   | What is the patient's PSA leve   |                          |       | ng/ML               |       |  |      |  |  |  |  |  |
|                      | 5.   | What is/was the patient's Gleason score (range: 2 to 10)?  |                          |       |                     |       |  |      |  |  |  |  |  |
|                      |  | □ <=6  |                          |       |                     |       |  |      |  |  |  |  |  |
|                      | 6.   | Has the cancer spread to any of the regional lymph nodes (N1 disease)?   |                          |       |                     |       |  |      |  |  |  |  |  |
|                      | 7.   | Will the pelvic lymph nodes be   |                          | ☐ Yes | ☐ No                | □ N/A |  |      |  |  |  |  |  |
|                      |  |  |                          |       |                     |       |  |      |  |  |  |  |  |

|                      | 8.  | How many fractions will be used for each phase?                              |                 |         |   |  |  |
|----------------------|---|--|-----------------|---------|---|--|--|
|                      |   | Phase 1  | Phase 2         | Phase 3 | Treatment Technique   |  |  |
|                      |   |  |                 |         | Conventional isodose planning, complex  Electron Beam Therapy |  |  |
|                      |   |  |                 |         |   |  |  |
|                      |   |  |                 |         | 3D conformal  |  |  |
|                      |   |  |                 |         | Intensity Modulated Radiation Therapy (IMRT)                  |  |  |
|                      |   |  |                 |         | Tomotherapy (IMRT)  |  |  |
|                      |   |  |                 |         | Rotational Arc Therapy/VMAT                                   |  |  |
|                      |   |  |                 |         | Proton Beam Therapy   |  |  |
|                      |   |  |                 |         | Stereotactic Body Radiation Therapy (SBRT)                    |  |  |
|                      |   |  |                 |         | Low Dose Rate (LDR) Brachytherapy                             |  |  |
| uo                   |   |  |                 |         | High Dose Rate (HDR) Brachytherapy                            |  |  |
| mat                  |   |  |                 |         | N/A   |  |  |
| Clinical Information | 9.  |  |                 |         |   |  |  |
|                      | Please be prepared to submit consult note, results of imaging from the past 60 days and radiation prescription or clinical treatment plan in order to expedite the review process. Failure to provide all |  |                 |         |   |  |  |
|                      | ۸ddit   | relevant information may result in a delay.  dditional Comments/Information: |                 |         |   |  |  |
|                      | Addii   | uonai Comi   | TIETILS/ITIIOTI | пацоп.  |   |  |  |
|                      |   |  |                 |         |   |  |  |
|                      |   |  |                 |         |   |  |  |
|                      |   |  |                 |         |   |  |  |
|                      |   |  |                 |         |   |  |  |
|                      |   |  |                 |         |   |  |  |
|                      |   |  |                 |         |   |  |  |
|                      |   |  |                 |         |   |  |  |
|                      |   |  |                 |         |   |  |  |
|                      |   |  |                 |         |   |  |  |
|                      |   |  |                 |         |   |  |  |
|                      |   |  |                 |         |   |  |  |